

## Daily evidence digest

2 February 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### Consumer interpretation of COVID-19 self-test kits, Omicron BA.1 & BA.2 in household transmission, building an evidence ecosystem

#### Peer reviewed journals featured:

- Randomised clinical trials on:
  - How consumers interpret and act on results from at-home COVID-19 self-test kits [here](#)
  - A multicomponent intervention to increase COVID-19 vaccine coverage in skilled nursing facilities [here](#)
- Observational studies on:
  - T cell responses to SARS-CoV-2 spike and Omicron [here](#)
  - Influence of state reopening policies on COVID-19 mortality in the US [here](#)
  - Vaccine elicitation of cellular immunity to Omicron [here](#)
- A modelling study on global equitable access to COVID-19 vaccines [here](#) and associated commentary [here](#)
- A case study on the Relational Gestalt approach to building a COVID-19 community of practice in a hospital setting [here](#)

#### Letters and correspondence discussed:

- Developing countries can make the mRNA vaccines they need [here](#)

#### Pre-peer review articles featured:

- Transmission of Omicron VOC subvariants BA.1 and BA.2 in Danish households [here](#)
- N Gene Target Failure (NGTF) for detection of Omicron [here](#)
- Acute upper airway disease in children with the Omicron variant [here](#)
- Wastewater monitoring of the transition from Delta to Omicron [here](#)
- Serum neutralising activity of Spikevax (Moderna) against the Omicron variant [here](#)
- Clinical benefit of casirivimab-imdevimab treatment for high-risk patients with Delta infection [here](#)
- Serial intervals of the Omicron and Delta variants in Belgium based on contact tracing data [here](#)
- Limit of detection for rapid antigen testing of the Omicron variant [here](#)

## Guidance and reports

- The World Health Organization published:
  - Updates of its COVID-19 vaccine tracker [here](#) and the landscape of observational studies on the effectiveness of COVID-19 vaccination [here](#)
  - An online course on implementation of SARS-CoV-2 antigen-detection rapid tests [here](#)
- The Canadian National Collaborating Centre for Methods and Tools updated its review on risk factors associated with severe COVID-19 outcomes in children 12 years and under [here](#)
- The National COVID-19 Clinical Evidence Taskforce released updated its recommendations on paxlovid and molnupiravir and its clinical flowcharts [here](#)

## News and blogs

- Building an evidence ecosystem – what’s worked in the pandemic [here](#)
- The long-term impacts of COVID-19 on health systems and clinicians [here](#)
- Molnupiravir in unvaccinated COVID-19 patients [here](#)
- Omicron sub-lineage BA.2 may have “substantial growth advantage” [here](#)
- Will Omicron end the pandemic? [here](#)

[Click here](#) to subscribe to the daily evidence digest.

### Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).